Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice - PubMed (original) (raw)
- PMID: 3708611
Comparative Study
Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice
J Plowman et al. Cancer Treat Rep. 1986 May.
Abstract
Flavone acetic acid, given on Days 2 and 9 at a dose of 267 mg/kg, inhibited tumor growth completely in 60%-80% of mice with early-stage Colon Adenocarcinoma 38. The therapeutic efficacy of the flavone against this tumor was retained when the sites of tumor implantation and drug administration were separated. Flavone acetic acid also caused regression of advanced (500-mg) Colon 38 tumors, with greatest efficacy observed following administration of high individual dose rather than high total dose. Unlike many previous potential anticancer agents, only modest activity was observed for this compound against either P388 or L1210 leukemia.
Similar articles
- A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
Atassi G, Dumont P, Kabbe HJ, Yoder O. Atassi G, et al. Drugs Exp Clin Res. 1988;14(9):571-4. Drugs Exp Clin Res. 1988. PMID: 3229319 - Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ, Burns-Horwitz PE, Czerniak PM, Diamond RJ, Diamond MA, Miller JL, Page RJ, Dexter DL, Chen SF, Sun JH, et al. McRipley RJ, et al. Cancer Res. 1994 Jan 1;54(1):159-64. Cancer Res. 1994. PMID: 8261436 - Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S, Mian AM. Furusawa S, et al. Cancer Treat Rep. 1987 May;71(5):441-6. Cancer Treat Rep. 1987. PMID: 3567967 - [Antitumor activity of polyanion and its application for drug delivery system of antitumor drugs].
Hirano T, Ohashi S, Todoroki T, Inaba M, Tsukagoshi S. Hirano T, et al. Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):542-7. Gan To Kagaku Ryoho. 1990. PMID: 2138872 Review. Japanese. - Flavonoids: a new class of anticancer agents? Preclinical and clinical data of flavone acetic acid.
Armand J, De Forni M, Recondo G, Cals L, Cvitkovic E, Munck J. Armand J, et al. Prog Clin Biol Res. 1988;280:235-41. Prog Clin Biol Res. 1988. PMID: 3051027 Review. No abstract available.
Cited by
- Clinical development and informatics analysis of natural and semi-synthetic flavonoid drugs: A critical review.
Xu K, Ren X, Wang J, Zhang Q, Fu X, Zhang PC. Xu K, et al. J Adv Res. 2024 Sep;63:269-284. doi: 10.1016/j.jare.2023.11.007. Epub 2023 Nov 8. J Adv Res. 2024. PMID: 37949300 Free PMC article. Review. - Trial watch: STING agonists in cancer therapy.
Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Le Naour J, et al. Oncoimmunology. 2020 Jun 16;9(1):1777624. doi: 10.1080/2162402X.2020.1777624. Oncoimmunology. 2020. PMID: 32934881 Free PMC article. Review. - Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy.
Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, Yin J, Zhang W, Zhou H, Liu Z. Zheng J, et al. Mol Cancer. 2020 Aug 27;19(1):133. doi: 10.1186/s12943-020-01250-1. Mol Cancer. 2020. PMID: 32854711 Free PMC article. Review. - Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
Rivera Vargas T, Benoit-Lizon I, Apetoh L. Rivera Vargas T, et al. Eur J Cancer. 2017 Apr;75:86-97. doi: 10.1016/j.ejca.2016.12.028. Epub 2017 Feb 20. Eur J Cancer. 2017. PMID: 28219022 Free PMC article. Review. - Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L, Gajewski TF. Corrales L, et al. Clin Cancer Res. 2015 Nov 1;21(21):4774-9. doi: 10.1158/1078-0432.CCR-15-1362. Epub 2015 Sep 15. Clin Cancer Res. 2015. PMID: 26373573 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources